Outlook Therapeutics, Inc.
OTLK · NASDAQ
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Market Cap | $99,052 | $55,285 | $258,738 | $331,307 |
| - Cash | $14,928 | $23,392 | $17,397 | $14,477 |
| + Debt | $29,738 | $35,555 | $10,958 | $11,902 |
| Enterprise Value | $113,862 | $67,449 | $252,299 | $328,733 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$114 | -$44 | -$205 | -$262 |
| % Margin | – | – | – | – |
| EBITDA | -$72,093 | -$57,376 | -$64,357 | -$51,511 |
| % Margin | – | – | – | – |
| Net Income | -$75,367 | -$58,983 | -$66,052 | -$53,163 |
| % Margin | – | – | – | – |
| EPS Diluted | -4.06 | -4.72 | -6.23 | -6.96 |
| % Growth | 14% | 24.2% | 10.5% | – |
| Operating Cash Flow | -$68,794 | -$42,973 | -$56,675 | -$54,253 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$68,794 | -$42,973 | -$56,675 | -$54,253 |